Professional Documents
Culture Documents
Beta Blockers - A Discovery That Transformed Cardiac Disease Management! - The Economic Times
Beta Blockers - A Discovery That Transformed Cardiac Disease Management! - The Economic Times
Beta Blockers - A Discovery That Transformed Cardiac Disease Management! - The Economic Times
Sensex 72,822.91 114.75 Search Stock Quotes, News, Mutual Funds and more
Canara Robeco Small C… 31.15 % INVEST NOW
Home ETPrime Markets News Industry Rise Politics Wealth Mutual Funds Tech Careers Opinion NRI Panache Spotlight •
•
Auto Banking/Finance Cons. Products Energy Renewables Ind'l Goods/Svs Healthcare/Biotech Services Media/Entertainment More
Business News › Industry › Healthcare/Biotech › Healthcare › Beta Blockers – A discovery that transformed cardiac disease management!
The Economic Times daily newspaper is available online now. Read Today's Paper
ADVERTORIAL
Synopsis
The advent of selective beta-blockers has transformed cardiovascular medicine by
providing clinicians with a range of tailored treatment options. Read to know more
Bisoprolol, for instance, has gained the trust of patients worldwide for over 3
decades. It is widely utilised as a reliable and well-established medication in
the management of various conditions. Its selectivity for beta-1 receptors
made it a favourable choice in patients with concomitant respiratory
conditions.
The most prominent question that arises in our mind is how beta-blockers
work. These medications exert their eYects by blocking the release of stress
hormones, such as adrenaline and noradrenaline, in speci]c areas of the body.
As a result, they slow down the heart rate and decrease the force with which
blood is pumped throughout the body. Additionally, beta blockers can inhibit
the production of a hormone called angiotensin II by the kidneys,
contributing to the signi]cant lowering of blood pressure.
Researchers and cardiologists have found strong evidence that taking a beta
blocker after a heart attack decreases the chances of early death by 44%.
Beta-blockers are also known to improve long-term outcomes in heart failure,
blood pressure control and coronary diseases. Beta-blockers have been
extensively used globally, and the cardio-selective ones are known to be well
tolerated in most patients, leading to high compliance among patients.
✕
MORE STORIES FOR YOU
Ka-Ching: How global drug makers are riding on luck in
their pursuit of blockbuster drugs, vaccines
FEB 15, 2024
Therefore, we, at Merck, on this day, pay our tributes to Sir James Whyte Black
for the novel discovery of Beta-blockers on his 99th birth anniversary. (14 June
1924 – 22 March 2010).
Dr Jamshed J Dalal, Mumbai, said, “Beta blockers are important drugs in the
management of the whole spectrum of cardiovascular disease. They are used
in the treatment of hypertension, heart failure, coronary artery disease,
cardiomyopathies and arrhythmias. Indians have a higher heart rate than
Westerners, and beta blockers help stabilise it. They not only relieve symptoms
but often improve survival. They are also used for tremors, migraine and
glaucoma. They have been extensively used in India for many decades and
helped millions of people. For this, we owe gratitude to Sir James Black, who
developed this molecule.”
(Catch all the Business News, Breaking News Budget 2024 News, Budget...more
2024 Live Coverage, Events and Latest News U
Download The Economic Times News App to get Daily Market Updates & Live Business News.
NEXT STORY
Synopsis
A rising middle-class and an aging population have boosted demand for private medical
services across Asia, which in turn, is seeing massive consolidation and heightened deal
activity in the healthcare sector.
Agencies
Mumbai: Global buyout funds EQT
(formerly Baring PE Asia-EQT), TPG
Capital and KKR are among those
evaluating the acquisition of a
controlling stake held by CVC Capital
in Bengaluru-based specialty cancer
hospital chain Healthcare Global
Enterprises (HCG), sources told ET.
Representative Image
The US PE fund bought a controlling stake in HCG in June 2020 for about Rs
1,049 crore by buying new shares and convertible warrants. It acquired more
shares later through a mandatory open oYer.
✕
MORE STORIES FOR YOU
Fundamental Radar: Three factors to drive 15% sales
CAGR for Apollo Hospitals, says Sneha Poddar
FEB 20, 2024
As on February 18, CVC stake in HCG would be worth around Rs 3,236 crore.
The deal would involve an open oYer for an additional 26% of the company.
The current market value of the hospital chain is Rs 5,357.38 crore. A recent
report by brokerage ]rm JeYeries also highlighted that CVC’s investment in
the cancer hospital chain has increased 2.7 times in less than three years.
In the past one month, the HCG stock is up 10% as the sale gathers
momentum.
CVC Capital is working with two Wall Street advisors for the sale that has
been launched in recent weeks. The oYicial sale process was launched
recently.
Ajai Kumar told ET that he is not looking to sell his stake and exit.
EQT declined to comment. CVC, TPG and KKR were not available for
comment.
Both these funds are involved in the biggest hospital deals involving private
equity (PE) investors in India. While KKR had one of its big pay days exiting
Max Healthcare in what was the largest block deal in the Indian stock
market history, TPG has backed several hospital chains but its largest bet has
been Manipal. Last year, TPG, an investor in Manipal since 2015, chose to fully
exit Ranjan Pai’s hospital chain by selling its stake to Temasek, but it also
decided to reinvest in Manipal via a new fund, albeit with a smaller holding.
Even EQT that has traditionally been overweight on tech and BPO deals has
been doubling down on healthcare. In 2022, EQT bought Hyderabad-
headquartered super specialty hospital AIG (Asian Institute of
Gastroenterology), pipping TPG. Last September, it acquired 60-65% of Indira
IVF for $650-700 million, the largest provider of fertility services in India and
also among the top ]ve globally in terms of annual in-vitro fertilisation (IVF)
cycles, for a billion-dollar valuation, in a headline-grabbing deal.
The debt-fuelled expansion and Covid-19 pandemic that disrupted cancer care
services have massively dented the company's ]nancial performance,
particularly in FY21.
The timely equity infusion by CVC and the appointment of Raj Gore as CEO in
February 2021, who prioritised operational eYiciency, cost optimisation and
rationalisation of bed capacities, have helped HCG to get back in the pink of
health.
The company said it is striving to achieve 20% ebitda margin and revenue
growth above the market growth rate of 10-11%. The net debt stood at Rs 367
crore as on December 2023.
The consolidated revenue grew by 21% during FY23 on the back of increased
admissions and procedures performed. The momentum was sustained in
H1FY24, with the company reporting growth of 14.5% on Yo-Y basis.
While in absolute terms, the pro]t before depreciation, interest and tax
(PBDIT) of the company grew but PBDIT margins improved marginally from
17.06% in FY22 to 17.60% in FY23 as increasing share of low-margin medical
oncology and continuing losses in some of the new centres like south Mumbai
and Kolkata limited margin gains. Nevertheless, these new centres have been
witnessing increasing footfalls and are likely to turnaround in the near term.
HCGEL is ]rmly placed to tap the increasing demand for cancer treatment,
which would continue to drive the revenue growth, said CARE Ratings in a
recent credit note.
HCG has also been looking to acquire cancer hospitals. In FY24 alone, HCG
announced acquisitions of 120-bed Nagpur Cancer Hospital and Research
Institute and 100-bed SRJ CBCC Cancer Hospital in Indore, giving the
hospital chain a ]rm footing in central India and south India.
Eqt Kkr HCG CVC Capital TPG Capital Block Deal Stock Market Bengaluru Specialty Cancer Hospital
(Catch all the Business News, Breaking News Budget 2024 News, Budget...more
2024 Live Coverage, Events and Latest News U
Download The Economic Times News App to get Daily Market Updates & Live Business News.
Trending Now
Maruti Suzuki Ertiga RBI MPC Meet Live Budget 2024 Highlights Budget 2024 Real Estate Railways Budget 2024 India auto sales september MORE
Hot On Web
Sensex Today Suhani Bhatnagar Death Bharat Bandh Live CTET Result PM Modi UAE Visit EPFO Interest Rate Hike MORE
Top Calculators
Standard Deviation Calculator Income Tax Calculator Age Calculator Time Calculator BMI Calculator GPA Calculator Statistics Calculator MORE
Top Slideshow
Youve Been Doing It Wrong Hg Infra Engineering Itc Income Tax Rule Change Salarie… Youve Been Doing It Wrong Itc MORE
Top Videos
Adani Enterprises Adani Ports A… Air Indias Mega 80 Billion Deal … Chatgpt Vs Bard Google Micros… Adani Groups Cfo Jugeshinder S… MORE
Top Definitions
Monetary Policy Advertising Commercial Bank Perfect Competition Non Performing Assets MORE
Private Companies
Campa Cola Co Pvt Ltd Excellent Escort Services Private… Vihaan Direct Selling India Priva… Awpl Ayurveda Private Limited MORE
Copyright © 2024 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service BACK TO TOP